Multiple approaches show benefit in treating orchialgia
In this interview, Jamin Brahmbhatt, MD, gives his take on several studies of orchialgia and chronic prostatitis/chronic pelvic pain syndrome presented at the 2018 AUA annual meeting.
Two alternative therapies for the treatment of men with orchialgia showed positive results in studies presented at the AUA annual meeting in San Francisco. A third study on another pain-related condition in men found that the addition of low-dose tadalafil (Cialis) to levofloxacin (Levaquin) is well tolerated and significantly improved chronic prostatitis/chronic pelvic pain syndrome symptoms.
An AUA press briefing on the studies was moderated by Jamin Brahmbhatt, MD, of Orlando Health in Clermont, FL. The studies examining orchialgia treatment demonstrated improved symptoms with physical therapy in men who have undergone previous medical and surgical interventions and with the use of trigger point dry needling as a component of physical therapy.
“Dry needling, which has already been used for patients with other forms of chronic pain, including interstitial cystitis, is now being used in men with chronic testicular pain or orchialgia. The study found that there were definitely benefits” when dry needling was added to physical therapy, Dr. Brahmbhatt said in a Urology Times video interview.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
